Standpoints

Please include Keytruda (pembrolizumab) in the indication ca endometrium in case of a final decision of the Ministry of Health of the Slovak Republic in the DRG as an attributable item.

NA-Keytruda (pembrolizumab) in the indication KN868 ca endometrial

patients with endometrial cancer requiring first-line treatment for primary advanced or recurrent cancer during hospitalisation according to the above IO

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

Please include Keytruda (pembrolizumab) in the indication NSCLC in case of a valid decision of the Ministry of Health of the Slovak Republic as of 1.1.2026 in the DRG as a creditable item.

NA-Keytruda (pembrolizumab) is pending ID34154 in the indication in question

nSCLC patients requiring first-line treatment for metastatic squamous NSCLC with PD-L1 TPS 1-49% during hospitalization according to the above IO

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

Please include Keytruda (pembrolizumab) in the indication ca stomach and GEJ in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as an attributable item.

NA - Keytruda (pembrolizumab) is pending ID35514 in the indication in question

patients with HER2-negative gastric cancer and GEJ requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation according to the above IO

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.

Requirement for PP medicine - tenecteplase

The opinion is set out in feedback number 659 - https://www.cksdrg.sk/sk/spatna-vazba/stanoviska/659

Please include Keytruda (pembrolizumab) in the case of a final decision of the Ministry of Health of the Slovak Republic from 1.1.2026 in the DRG as a creditable item

on - ID35033 is pending in the indication in question, with an expected date of inclusion in the ZKL in 2025

patients with oesophageal cancer requiring first-line treatment for locally advanced, unresectable or metastatic cancer during hospitalisation

The indication restrictions (IOs) in the DRG system are aligned with the IOs that are listed in the categorisation list of medicines. As the SK-DRG system is updated only once a year and new indications enter the categorisation list all year round, in order to avoid misalignment of the two systems, the reporting of indication restrictions has been transferred to marker reporting, which makes the DRG system more flexible and as soon as a medicine is categorised under a new indication, it can also be reported under the DRG system.